Result:Very Good· Market: Up#Broad based#Margin expansion
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 29.62 | 11.9% | 57.4% |
| Total Income | 31.77 | 9.1% | 52.3% |
| Expenditure | 24.83 | 19.2% | 44.8% |
| PBT | 6.94 | 16.2% | 86.7% |
| Net Profit | 5.39 | 3.1% | 110.1% |
| OPM | 18.52% | 4.86pp | 6.93pp |
| NPM | 16.96% | 0.98pp | 4.67pp |
| EPS | 15.08 | 3.1% | 110.0% |
Pharma revenue grew 57% YoY with OPM expanding ~690bps (11.6%→18.5%) and PAT up 110%, a broad-based, core-driven standout rather than a one-off beat.
Informational and educational content only. Not investment advice.